AXSM
Axsome Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AXSM
Axsome Therapeutics, Inc.
A biopharmaceutical company that develops novel therapies for the management of central nervous system (CNS) disorders
22 Cortlandt Street, 16th Floor, New York, New York 10007
--
Axsome Therapeutics, Inc., was founded in January 2012. The company is a clinical-stage biopharmaceutical company developing novel treatments for pain and other central nervous system or central nervous system, disease management. By focusing on this therapeutic area, they are addressing a significant and growing market where current therapeutic options are limited or insufficient. Their goal is to become a fully integrated biopharmaceutical company to develop and commercialize extended treatment options for healthcare professionals to improve life differentiation therapy for patients with pain and other CNS diseases.
Earnings Call
Q1/2025
Estimate EPS-1.35
Actual EPS-1.22
Estimate Revenue119.28M
Actual Revenue121.46M
Axsome Therapeutics' Q1 2025: Unraveling Contradictions in Auvelity Marketing and AD Submission Strategies
May 05,2025 07:41
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-1.07
Actual EPS-0.97
Estimate Revenue138.02M
Actual Revenue150.04M
Navigating Contradictions: Insights from the Latest SYMBRAVO Earnings Call on Payer Coverage, Sales Force Impact, and AXS-12 Positioning
Aug 04,2025 03:01
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.9
Actual EPS-0.95
Estimate Revenue162.99M
Actual Revenue171.00M
Axsome Therapeutics' Q3 2025 Earnings Call: Contradictions in Sales Force Expansion, Reboxetine Strategy, and AXS-05 Commercialization Plans
Nov 03,2025 03:00
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AXSM has released its 2025 Q3 earnings. EPS was reported at -0.95, versus the expected -0.9, missing expectations. The chart below visualizes how AXSM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AXSM has released its 2025 Q3 earnings report, with revenue of 170.99M, reflecting a YoY change of 63.22%, and net profit of -47.23M, showing a YoY change of 26.89%. The Sankey diagram below clearly presents AXSM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
